at $15/sh NPV. assuming revenue growth
until 2O25-2O27, when EU and US patents expire. Orkambi (SS8/sh) is VRTX's largest
growth opportunity and expected ... from 2016-2027E using a WACC of 8.5%. We derive the following values:
Kalydeco
(521/share), VX-809 (566/share), VX661 (516/share), and inclusive of 54/share
of net cash. We believe